gsk boston - Search News

Order byBest matchMost fresh

News

GSK buys liver drug from Boston Pharmaceuticals

GSK buys liver drug from Boston Pharmaceuticals for up to $2 billion

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the promising field of liver therapies.

Continue reading

PharmExec · 9h

GSK Acquires Boston Pharmaceuticals’ Novel FGF21 Analog for Steatotic Liver Disease

· 11h · on MSN

GSK to buy liver disease drug for up to $2 billion

12h

GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

20h

GSK to buy efimosfermin for up to $2 billion

GSK will buy efimosfermin, a specialty medicine used to treat liver disease from Boston Pharmaceuticals, for up to $2 billion ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results